Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03426540

Intravitreal Conbercept After Vitrectomy

Safety and Efficacy of Intravitreal Conbercept Injection After Vitrectomy for the Treatment of Early Proliferative Diabetic Retinopathy

Sponsor: Tianjin Medical University Eye Hospital

Conditions Early Proliferative Diabetic Retinopathy

Interventions Conbercept

Updated 6 times since 2018 Last updated: Apr 29, 2019 Started: Jan 1, 2017 Primary completion: Mar 30, 2018 Completion: Feb 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Early Proliferative Diabetic Retinopathy and is currently completed. Tianjin Medical University Eye Hospital leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
May 2019 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — May 2019 [monthly]

Active Not Recruiting EARLY_PHASE1

▶ Show 1 earlier version

Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting EARLY_PHASE1

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University Eye Hospital

Data source: Tianjin Medical University Eye Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.